Literature DB >> 12970118

Thrombin formation.

Kenneth G Mann1.   

Abstract

The generation of the enzyme thrombin from its precursor prothrombin is the central event of the blood coagulation process, which is essential to hemostasis and the culprit in thrombosis. Thrombin is produced by a complex series of proteolytic events that are initiated when cryptic tissue factor interacts with plasma factor VIIa to initiate the complex series of events leading to the formation of the blood coagulation enzyme complexes that lead to the efficient generation of the enzyme. During these processes, thrombin contributes to both the generation of the catalysts involved in its ultimate production and to the catalysts that lead to attenuation of its production. Thrombin-catalyzed events both enhance and diminish the process of thrombin generation, which is down-regulated by stoichiometric and dynamic inhibitory processes. The combinations of intensities of activation and inhibition processes provide tight regulation of the hemostatic process, establishing reaction thresholds, essentially leading to an "on/off" switch. This review provides a brief summary of the evolution of knowledge with respect to present-day concepts of thrombin generation via the tissue factor pathway and its regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970118     DOI: 10.1378/chest.124.3_suppl.4s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  65 in total

1.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

2.  Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Authors:  Teddy Kosoglou; Walter K Kraft; Bharath Kumar; Paul Statkevich; Fengjuan Xuan; Lei Ma; Lisa K Jennings; James E Schiller; Ronald B Langdon; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2012-02-08       Impact factor: 2.953

3.  Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns.

Authors:  Joshua H Wong; Jonathan Dukes; Robert E Levy; Brandon Sos; Sara E Mason; Tina S Fong; Ethan J Weiss
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

Review 4.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

5.  Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

6.  Carbohydrates and activity of natural and recombinant tissue factor.

Authors:  Jolanta Krudysz-Amblo; Mark E Jennings; Kenneth G Mann; Saulius Butenas
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

7.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

Review 8.  Biochemomechanics of intraluminal thrombus in abdominal aortic aneurysms.

Authors:  J S Wilson; L Virag; P Di Achille; I Karsaj; J D Humphrey
Journal:  J Biomech Eng       Date:  2013-02       Impact factor: 2.097

9.  Structure-based predictive models for allosteric hot spots.

Authors:  Omar N A Demerdash; Michael D Daily; Julie C Mitchell
Journal:  PLoS Comput Biol       Date:  2009-10-09       Impact factor: 4.475

Review 10.  Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.

Authors:  Marc Cohen
Journal:  Cardiovasc Drugs Ther       Date:  2009-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.